U.S. TRANSTHYRETIN AMYLOIDOSIS TREATMENT MARKET ANALYSIS

U.S. Transthyretin Amyloidosis Treatment Market, By Type (Hereditary Transthyretin Amyloidosis (hATTR-CM) and Wild Type Amyloidosis), By Drug Type (Tafamidis, Diflunisal, Inotersen, Patisiran, Tolcapone, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Published In : Feb 2025
Code : CMI1919
Pages :116
Formats :
Excel and PDF
Industry : Pharmaceutical

U.S. Transthyretin Amyloidosis Treatment Market Size and Trends

The U.S. transthyretin amyloidosis treatment market is estimated to be valued at USD 65.4 Mn in 2025 and is expected to reach USD 124.4 Mn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.6% from 2025 to 2032.

U.S. Transthyretin Amyloidosis Treatment Market Key Factors

To learn more about this report, Request sample copy

Increasing research and development efforts aimed at innovative treatments, alongside heightened collaborations between pharmaceutical companies and research institutions for clinical trials, are crucial in boosting demand for transthyretin amyloidosis treatment. Additionally, awareness initiatives led by non-profit organizations and support groups are expected to propel market growth. However, challenges such as the scarcity of approved drugs and high costs associated with treatment may hinder this growth trajectory in the coming years.